SEC Form 4 · accession 0000914190-17-000320
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J J Finkelstein
Officer — President and CEO · Director
Period of report
Oct 19, 2017
Accepted (ET)
Oct 20, 2017 · 3:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 19, 2017 | C | 125,347 | $0.15 | A | 1,513,535 | D | |
| Common Stock | Oct 19, 2017 | X | 20,000 | $0.15 | A | 1,533,535 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory Note (right to buy)F1 | $0.15 | Oct 19, 2017 | C | 125,347 | D | Oct 19, 2012 | Oct 19, 2017 | Common Stock | 125,347 | 0 | D |
| Common Stock Warrant (right to buy) | $0.15 | Oct 19, 2017 | X | 20,000 | D | Apr 19, 2013 | Oct 19, 2017 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The Convertible Promissory Note in the principal amount of $15,000 accrued $3,802.05 in interest and both principal and interest were converted into 125,347 shares of common stock at a conversion price of $0.15 per share.